Need help finding what you are looking for?
Contact Us
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1398876
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1398876
Europe Age-Related Updated Macular Degeneration (AMD) Disease - ANTI VEGF Market - Industry Trends and Forecast to 2033
PUBLISHED:
PAGES: 147 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
Europe Age-Related Macular Degeneration (AMD) disease - anti VEGF market is expected to reach USD 7,290.17 million by 2031 from USD 4,439.22 million in 2023, growing with a CAGR of 6.5% in the forecast period of 2024 to 2031.
Market Segmentation
Europe Age-Related Macular Degeneration (AMD) Disease - Anti VEGF Market, By Type (Dry AMD and Wet AMD), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare, Others), Distribution Channel (Retail Sales, Direct Tenders, and Others), Country (France, Italy U.K., Spain, Russia, Austria, Netherlands, Hungary, Poland, Switzerland, Turkey, Norway, Lithuania, Ireland, and rest of Europe) - Industry Trends and Forecast to 2031.
Overview of Europe Age-Related Macular Degeneration (AMD) Disease - ANTI VEGF Market Dynamics
- Driver
- Rising prevalence of age-related macular degeneration
- Restraint
- High-Cost of treatment and procedures
- Opportunity
- Increase in awareness and treatment seeking rate of AMD
Market Players
Some of the major market players operating in the Europe Age-Related Macular Degeneration (AMD) disease - anti VEGF market are listed below:
- Regeneron Pharmaceuticals Inc. ()
- Novartis AG
- Bayer AG
- IVERIC bio, Inc., An Astellas Company
- Genentech, Inc. (A subsidiary of F. Hoffmann-La Roche Ltd)
- Johnson & Johnson Services, Inc.
- KODIAK SCIENCES INC.
- Adverum Biotechnologies, Inc.
- Biogen
- Sylentis, S.A.
- MeiraGTx Limited
- Ionis Pharmaceuticals
- Gensight Bilogics
- OGUGEN, INC.
- Outlook Therapeutics, Inc.
- REGENXBIO Inc.
TABLE OF CONTENTS
1 INTRODUCTION 16
- 1.1 OBJECTIVES OF THE STUDY 16
- 1.2 MARKET DEFINITION 16
- 1.3 OVERVIEW OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET 16
- 1.4 LIMITATIONS 18
- 1.5 MARKETS COVERED 18
2 MARKET SEGMENTATION 20
- 2.1 MARKETS COVERED 20
- 2.2 GEOGRAPHICAL SCOPE 21
- 2.3 YEARS CONSIDERED FOR THE STUDY 22
- 2.4 CURRENCY AND PRICING 22
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 23
- 2.6 MULTIVARIATE MODELLING 26
- 2.7 TYPE LIFELINE CURVE 27
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 28
- 2.9 DBMR MARKET POSITION GRID 29
- 2.10 MARKET END USER COVERAGE GRID 30
- 2.11 VENDOR SHARE ANALYSIS 31
- 2.12 SECONDARY SOURCES 32
- 2.13 ASSUMPTIONS 32
3 EXECUTIVE SUMMARY 33
4 PREMIUM INSIGHTS 35
- 4.1 PESTEL 36
- 4.2 PORTERS_ 37
- 4.3 PRICING ANALYSIS 38
- 4.4 STRATEGIC INITIATIVES 39
5 REGULATORY FRAMEWORK 40
6 MARKET OVERVIEW 43
- 6.1 DRIVERS 45
- 6.1.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION 45
- 6.1.2 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYERS 45
- 6.1.3 INCREASE IN PIPELINE PRODUCTS 46
- 6.1.4 INCREASING GERIATRIC POPULATION 47
- 6.1.5 INCREASING PRODUCT APPROVAL FOR AGE-RELATED MACULAR DEGENERATION (AMD) 48
- 6.2 RESTRAINTS 48
- 6.2.1 HIGH COST OF TREATMENT AND PROCEDURES 48
- 6.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS 49
- 6.3 OPPORTUNITIES 49
- 6.3.1 INCREASING RESEARCH AND DEVELOPMENT 49
- 6.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE OF AMD 50
- 6.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT 50
- 6.4 CHALLENGES 50
- 6.4.1 LIMITED ACCESS TO TREATMENT 50
- 6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR PRODUCTS 51
7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE 52
- 7.1 OVERVIEW 53
- 7.2 WET AMD 56
- 7.2.1 MEDICATIONS 57
- 7.2.1.1 ANTI-VEGF THERAPY 57
- 7.2.1.2 OTHERS 57
- 7.2.2 SURGERY 57
- 7.2.1 MEDICATIONS 57
- 7.3 DRY AMD 58
8 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER 59
- 8.1 OVERVIEW 60
- 8.2 HOSPITALS 63
- 8.3 SPECIALTY CLINICS 64
- 8.4 AMBULATORY SURGICAL CENTERS 64
- 8.5 HOME HEALTHCARE 65
- 8.6 OTHERS 65
9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL 66
- 9.1 OVERVIEW 67
- 9.2 RETAIL SALES 70
- 9.2.1 HOSPITAL PHARMACIES 71
- 9.2.2 RETAIL PHARMACIES 71
- 9.2.3 OTHERS 71
- 9.3 DIRECT TENDER 72
10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION 73
- 10.1 EUROPE 75
- 10.1.1 GERMANY 78
- 10.1.2 FRANCE 80
- 10.1.3 U.K. 82
- 10.1.4 RUSSIA 84
- 10.1.5 ITALY 86
- 10.1.6 SPAIN 88
- 10.1.7 NETHERLANDS 90
- 10.1.8 SWITZERLAND 92
- 10.1.9 POLAND 94
- 10.1.10 TURKEY 96
- 10.1.11 AUSTRIA 98
- 10.1.12 HUNGARY 100
- 10.1.13 NORWAY 102
- 10.1.14 IRELAND 104
- 10.1.15 LITHUANIA 106
- 10.1.16 REST OF EUROPE 108
11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY LANDSCAPE 109
- 11.1 COMPANY SHARE ANALYSIS: EUROPE 109
12 SWOT ANALYSIS 110
13 COMPANY PROFILE 111
- 13.1 REGENERON PHARMACEUTICALS INC. 111
- 13.1.1 COMPANY SNAPSHOT 111
- 13.1.2 REVENUE ANALYSIS 112
- 13.1.3 COMPANY SHARE ANALYSIS 112
- 13.1.4 PRODUCT PORTFOLIO 113
- 13.1.5 RECENT DEVELOPMENTS 113
- 13.2 BAYER AG 114
- 13.2.1 COMPANY SNAPSHOT 114
- 13.2.2 REVENUE ANALYSIS 114
- 13.2.3 COMPANY SHARE ANALYSIS 115
- 13.2.4 PRODUCT PORTFOLIO 115
- 13.2.5 RECENT DEVELOPMENT 116
- 13.3 GENENTECH, INC. (A SUBSIDIARY OF F.HOFFMANN- LA ROCHE LTD) 117
- 13.3.1 COMPANY SNAPSHOT 117
- 13.3.2 COMPANY SHARE ANALYSIS 117
- 13.3.3 PRODUCT PORTFOLIO 118
- 13.3.4 RECENT DEVELOPMENT 118
- 13.4 NOVARTIS AG 119
- 13.4.1 COMPANY SNAPSHOT 119
- 13.4.2 REVENUE ANALYSIS 119
- 13.4.3 COMPANY SHARE ANALYSIS 120
- 13.4.4 PRODUCT PORTFOLIO 120
- 13.4.5 RECENT DEVELOPMENTS 121
- 13.4.5.1 AGREEMENT 121
- 13.5 IVERIC BIO (A SUBSIDIARY OF ASTELLAS PHARMA INC.) 122
- 13.5.1 COMPANY SNAPSHOT 122
- 13.5.2 REVENUE ANALYSIS 122
- 13.5.3 COMPANY SHARE ANALYSIS 123
- 13.5.4 PRODUCT PORTFOLIO 123
- 13.5.5 RECENT DEVELOPMENT 124
- 13.6 ADVERUM BIOTECHNOLOGIES, INC. 125
- 13.6.1 COMPANY SNAPSHOT 125
- 13.6.2 PRODUCT PORTFOLIO 125
- 13.6.3 RECENT DEVELOPMENT 126
- 13.7 BIOGEN 127
- 13.7.1 COMPANY SNAPSHOT 127
- 13.7.2 PRODUCT PORTFOLIO 127
- 13.7.3 RECENT DEVELOPMENT 127
- 13.8 GENSIGHT BIOLOGICS 128
- 13.8.1 COMPANY SNAPSHOT 128
- 13.8.2 REVENUE ANALYSIS 128
- 13.8.3 PRODUCT PORTFOLIO 129
- 13.8.4 RECENT DEVELOPMENTS 129
- 13.9 IONIS PHARMACEUTICALS 130
- 13.9.1 COMPANY SNAPSHOT 130
- 13.9.2 REVENUE ANALYSIS 130
- 13.9.3 PRODUCT PORTFOLIO 131
- 13.9.4 RECENT DEVELOPMENTS 131
- 13.10 JOHNSON &JOHNSON SERVICES, INC. 132
- 13.10.1 COMPANY SNAPSHOT 132
- 13.10.2 REVENUE ANALYSIS 132
- 13.10.3 PRODUCT PORTFOLIO 133
- 13.10.4 RECENT DEVELOPMENTS 133
- 13.11 KODIAK SCIENCES INC. 135
- 13.11.1 COMPANY SNAPSHOT 135
- 13.11.2 PRODUCT PORTFOLIO 135
- 13.11.3 RECENT DEVELOPMENTS 135
- 13.12 MEIRAGTX LIMITED 136
- 13.12.1 COMPANY SNAPSHOT 136
- 13.12.2 PRODUCT PORTFOLIO 136
- 13.12.3 RECENT DEVELOPMENTS 136
- 13.13 OCUGEN, INC. 138
- 13.13.1 COMPANY SNAPSHOT 138
- 13.13.2 PRODUCT PORTFOLIO 138
- 13.13.3 RECENT DEVELOPMENTS 139
- 13.14 OUTLOOK THERAPEUTICS, INC. 140
- 13.14.1 COMPANY SNAPSHOT 140
- 13.14.2 PRODUCT PORTFOLIO 140
- 13.14.3 RECENT DEVELOPMENT 140
- 13.15 REGENXBIO INC. 141
- 13.15.1 COMPANY SNAPSHOT 141
- 13.15.2 PRODUCT PORTFOLIO 141
- 13.15.3 RECENT DEVELOPMENTS 142
- 13.16 SYLENTIS, S.A. 143
- 13.16.1 COMPANY SNAPSHOT 143
- 13.16.2 PRODUCT PORTFOLIO 143
- 13.16.3 RECENT DEVELOPMENT 143
14 QUESTIONNAIRE 144
15 RELATED REPORTS 147
LIST OF TABLES
- TABLE 1 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
- TABLE 2 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 56
- TABLE 3 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 56
- TABLE 4 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 57
- TABLE 5 EUROPE DRY AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 58
- TABLE 6 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 63
- TABLE 7 EUROPE HOSPITALS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF, BY REGION, 2022-2031 (USD MILLION) 63
- TABLE 8 EUROPE SPECIALTY CLINICS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 64
- TABLE 9 EUROPE AMBULATORY SURGICAL CENTERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 64
- TABLE 10 EUROPE HOME HEALTHCARE IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 65
- TABLE 11 EUROPE OTHERS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 65
- TABLE 12 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 70
- TABLE 13 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 70
- TABLE 14 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 71
- TABLE 15 EUROPE DIRECT TENDER IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET, BY REGION, 2022-2031 (USD MILLION) 72
- TABLE 16 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY COUNTRY, 2022-2031 (USD MILLION) 75
- TABLE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
- TABLE 18 EUROPE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
- TABLE 19 EUROPE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 76
- TABLE 20 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 77
- TABLE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 77
- TABLE 22 EUROPE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 77
- TABLE 23 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
- TABLE 24 GERMANY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
- TABLE 25 GERMANY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 78
- TABLE 26 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 79
- TABLE 27 GERMANY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 79
- TABLE 28 GERMANY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 79
- TABLE 29 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
- TABLE 30 FRANCE WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
- TABLE 31 FRANCE MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 80
- TABLE 32 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 81
- TABLE 33 FRANCE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 81
- TABLE 34 FRANCE RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 81
- TABLE 35 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
- TABLE 36 U.K. WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
- TABLE 37 U.K. MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 82
- TABLE 38 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 83
- TABLE 39 U.K. AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 83
- TABLE 40 U.K. RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 83
- TABLE 41 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
- TABLE 42 RUSSIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
- TABLE 43 RUSSIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 84
- TABLE 44 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 85
- TABLE 45 RUSSIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 85
- TABLE 46 RUSSIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 85
- TABLE 47 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 86
- TABLE 48 ITALY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 86
- TABLE 49 ITALY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 86
- TABLE 50 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 87
- TABLE 51 ITALY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 87
- TABLE 52 ITALY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 87
- TABLE 53 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
- TABLE 54 SPAIN WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
- TABLE 55 SPAIN MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 88
- TABLE 56 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 89
- TABLE 57 SPAIN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 89
- TABLE 58 SPAIN RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 89
- TABLE 59 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
- TABLE 60 NETHERLANDS WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
- TABLE 61 NETHERLANDS MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 90
- TABLE 62 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 91
- TABLE 63 NETHERLANDS AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 91
- TABLE 64 NETHERLANDS RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 91
- TABLE 65 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
- TABLE 66 SWITZERLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
- TABLE 67 SWITZERLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 92
- TABLE 68 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 93
- TABLE 69 SWITZERLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 93
- TABLE 70 SWITZERLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 93
- TABLE 71 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
- TABLE 72 POLAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
- TABLE 73 POLAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 94
- TABLE 74 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 95
- TABLE 75 POLAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 95
- TABLE 76 POLAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 95
- TABLE 77 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
- TABLE 78 TURKEY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
- TABLE 79 TURKEY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 96
- TABLE 80 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 97
- TABLE 81 TURKEY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 97
- TABLE 82 TURKEY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 97
- TABLE 83 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
- TABLE 84 AUSTRIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
- TABLE 85 AUSTRIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 98
- TABLE 86 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 99
- TABLE 87 AUSTRIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 99
- TABLE 88 AUSTRIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 99
- TABLE 89 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 100
- TABLE 90 HUNGARY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 100
- TABLE 91 HUNGARY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 100
- TABLE 92 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 101
- TABLE 93 HUNGARY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 101
- TABLE 94 HUNGARY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 101
- TABLE 95 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 102
- TABLE 96 NORWAY WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 102
- TABLE 97 NORWAY MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 102
- TABLE 98 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 103
- TABLE 99 NORWAY AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 103
- TABLE 100 NORWAY RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 103
- TABLE 101 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 104
- TABLE 102 IRELAND WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 104
- TABLE 103 IRELAND MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 104
- TABLE 104 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 105
- TABLE 105 IRELAND AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 105
- TABLE 106 IRELAND RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 105
- TABLE 107 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 106
- TABLE 108 LITHUANIA WET AMD IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 106
- TABLE 109 LITHUANIA MEDICATIONS IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 106
- TABLE 110 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY END USER, 2022-2031 (USD MILLION) 107
- TABLE 111 LITHUANIA AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 107
- TABLE 112 LITHUANIA RETAIL SALES IN AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION) 107
- TABLE 113 REST OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET, BY TYPE, 2022-2031 (USD MILLION) 108
LIST OF FIGURES
- FIGURE 1 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 20
- FIGURE 2 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DATA TRIANGULATION 23
- FIGURE 3 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DROC ANALYSIS 24
- FIGURE 4 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: EUROPE VS REGIONAL MARKET ANALYSIS 25
- FIGURE 5 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: COMPANY RESEARCH ANALYSIS 25
- FIGURE 6 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: MULTIVARIATE MODELLING 26
- FIGURE 7 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: INTERVIEW DEMOGRAPHICS 28
- FIGURE 8 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: DBMR MARKET POSITION GRID 29
- FIGURE 9 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: END USER COVERAGE GRID 30
- FIGURE 10 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: VENDOR SHARE ANALYSIS 31
- FIGURE 11 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SEGMENTATION 34
- FIGURE 12 AN INCREASE IN THE PREVALENCE OF AGE-RELATED MACULAR DEGENERATION (AMD) AND GROWING GERIATRIC POPULATION ARE DRIVING THE GROWTH OF THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN THE FORECAST PERIOD OF 2024 TO 2031 35
- FIGURE 13 WET AMD SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET IN 2023 AND 2031 35
- FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET 44
- FIGURE 15 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2023 53
- FIGURE 16 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, 2024-2031 (USD MILLION) 54
- FIGURE 17 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, CAGR (2024-2031) 54
- FIGURE 18 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY TYPE, LIFELINE CURVE 55
- FIGURE 19 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2023 60
- FIGURE 20 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, 2024-2031 (USD MILLION) 61
- FIGURE 21 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, CAGR (2024-2031) 61
- FIGURE 22 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: BY END USER, LIFELINE CURVE 62
- FIGURE 23 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2023 67
- FIGURE 24 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION) 68
- FIGURE 25 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031) 68
- FIGURE 26 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE- ANTI VEGF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 69
- FIGURE 27 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VEGF MARKET: SNAPSHOT (2023) 74
- FIGURE 28 EUROPE AGE-RELATED MACULAR DEGENERATION (AMD) DISEASE - ANTI VGEF MARKET: COMPANY SHARE 2024 (%) 109
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.